Pegylated Interferon for the Adjuvant Treatment of Melanoma: FDA Approved, but What Is Its Role?

Abstract

The article by Herndon and colleagues on the approval of peginterferon-alfa-2b for the adjuvant treatment of patients with resected node-positive melanoma, published in this issue of The Oncologist, is examined, and the relevance of this therapy in clinical practice discussed.